SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

ANRO is trending due to recent FDA Fast Track designation for its ALTO-101 schizophrenia treatment, sparking optimism about its potential as a novel solution in a market with unmet needs. The community is discussing the significance of this milestone, potential for accelerated approval, and the company's broader pipeline. Increased trading volume and institutional ownership suggest growing confidence in Alto Neuroscience's prospects.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending as the community celebrates its recent listing on Robinhood, anticipating increased exposure and potential price growth. Discussions revolve around Floki's long-term potential, comparisons to other meme coins, and predictions for a significant rally. Some community members highlight Floki's ecosystem and utility, differentiating it from other meme coins.

Hillenbrand, Inc. is a global industrial company, which engages in providing engineered processing equipment and solutions. It operates through the Advanced Process Solutions and Molding Technology Solutions segments. The Advanced Process Solutions segment provides compounding, extrusion, and material handling, screening, and separating equipment, systems, and services for manufacturing and other industrial processes. The Molding Technology Solutions segment includes engineered and customized equipment, systems, and services in plastic technology and processing. It also operates through the following geographical segments: United States, China, India, Germany, and All Other Countries. The company was founded on November 1, 2007 and is headquartered in Batesville, IN.

Hillenbrand Inc

Hillenbrand is trending due to recent strategic moves, including considering a potential sale of the company's plastics division and exploring strategic alternatives for its Batesville business. Unusual options activity suggests bullish sentiment, while the community discusses the company's consolidation and potential for a significant move. Wall Street's EPS expectations and recent insider activity are also being closely monitored.

Maplebear, Inc. engages in the design and development of an online application that offers grocery delivery and pick-up services. The firm offers Instacart which enables users to connect with personal shoppers in the area who pick up and deliver groceries from local stores. The company was founded by Apoorva Mehta, Brandon Leonardo, and Max Mullen in 2012 and is headquartered in San Francisco, CA.

Maplebear Inc.

Instacart

Instacart ($CART) is trending due to analyst rating changes and community discussions around competition in the grocery delivery space. Analysts are split, with some downgrading the stock due to increased competition from Amazon, DoorDash, and Uber, while others remain bullish, citing strong fundamentals and growth potential. The community is actively debating the company's valuation, competitive advantages, and potential for a takeover.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

Satoshi Nakamoto ($SATOSHI) is trending as the community celebrates its anniversary and touts it as the 'Bitcoin of memes'. Discussions revolve around its timeless narrative, strong community, and potential for massive growth due to its association with the pseudonymous creator of Bitcoin. Many believe $SATOSHI embodies the identity of the entire crypto industry.

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics is trending as investors speculate about a potential acquisition, fueled by unusual options activity and a recent technical breakout on the charts. Community members are weighing positive regulatory and revenue updates against insider selling, while others discuss potential M&A scenarios in the pharmaceutical sector. Upcoming catalysts, including a PDUFA decision in October, are adding to the heightened interest in $ARQT.

First Horizon Corp. (Tennessee) operates as a financial holding company, which engages in the provision of checking accounts, savings products, mortgage banking, lending, and financing to individuals and businesses. It operates the business through three segments: Regional Banking, Specialty Banking, and Corporate. The Regional Banking segment offers financial products and services, including traditional lending and deposit taking, to retail and commercial customers. The Specialty Banking segment consists of lines of business that deliver product offerings and services with specialized industry knowledge. The Corporate segment focuses on corporate support functions such as risk management, audit, accounting, finance, executive office, and corporate communications. The company was founded by Frank S. Davis in 1864 and is headquartered in Memphis, TN.

First Horizon Corporation

First Horizon is trending due to unusual options activity and analyst rating adjustments, sparking discussions about its potential. Community talking points include speculation about future performance, potential acquisitions, and comparison to other regional banks. The stock's movements are also being analyzed in the context of broader sector trends and interest rate sensitivity.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending following news of trial updates and increased volume, leading to a surge past its 52-week high. Community members are actively speculating about a potential buyout and the implications of new partnerships. Discussions also revolve around the company's financial health and future growth prospects in the competitive pharmaceutical landscape.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending as traders discuss potential pullbacks and upcoming catalysts, with some eyeing the $40 mark. Community members are weighing bullish AI narratives against valuation concerns and potential market corrections, while also reacting to news impacting the broader semiconductor sector. Leveraged ETF dynamics and the influence of algorithms are also active points of discussion.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its association with cannabis culture and positions it as a cryptocurrency with a unique identity. The community emphasizes the cultural significance and longevity of the "weed culture". Some users are comparing Weedcoin to Bitcoin.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Beyond Tesla: Why GM and Ford Heavy ETFs Could Be Safer Bets Now?

GM and Ford-focused ETFs like RPV, MADE, and COWZ may offer investors stability as Tesla faces a post-subsidy demand cliff.  

Should Pacer US Cash Cows 100 ETF (COWZ) Be on Your Investing Radar?

Is Pacer US Cash Cows 100 ETF (COWZ) a Strong ETF Right Now?

Why Free Cash Flow Drives Superior Stock Performance

Here's why companies with high free cash flow often demonstrate high quality.

Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the Health and Human Services Department, led by Robert F. Kennedy Jr., plans to "drastically" cut federal funding for domestic HIV prevention.While cuts have not been finalized, the Wall Street Journal&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-administration-weighing-major-cuts-to-funding-for-domestic-hiv-prevention-8dcad39b?mod=Searchresults_pos1&amp;page=1&amp;mod=article_inline&amp;adobe_mc=MCMID%3D74537243080012175182679892959762943330%7CMCORGID%3DCB68E4BA55144CAA0A4C98A5%2540AdobeOrg%7CTS%3D1742440495&amp;_gl=1*1myqz7*_gcl_au*NTUzNDY5MDY4LjE3MzUyMTA0MzI.*_ga*MTg1Mzg3MjI1NS4xNzE4OTcyNDYz*_ga_K2H7B9JRSS*MTc0MjQ0MDIzNy4yNi4xLjE3NDI0NDA0OTMuNjAuMC4w">reported</a>, citing people familiar with the matter, that they could be announced soon as part of the Trump administration's broader budget reductions at the Centers for Disease Control and Prevention.Gilead, which has a portfolio of HIV prevention treatments such as Biktarvy and Descovy, risks a hit to revenues if the report turns out to be true.However, retail investors and Wall Street analysts remain largely unfazed for now.Retail sentiment for Gilead on Stocktwits climbed further into the 'extremely bullish' zone on Wednesday, with message volume up 57% following the news.&nbsp;<figure class="image"><img style="aspect-ratio:1318/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/GILD_sentiment_and_message_volume_as_of_March_19_png_baa27803b8.webp" alt="GILD sentiment and message volume as of March 19.png" width="1318" height="302"><figcaption>GILD sentiment and message volume as of March 19. | source: Stocktwits</figcaption></figure>Observers on the platform cited Gilead's dominance in HIV treatments, growing oncology presence, and strong free cash flow as reasons to hold on to the stock.<stembedurl>https://stocktwits.com/Bitcoin333/message/608542775</stembedurl><stembedurl>https://stocktwits.com/skcots131313/message/608543583</stembedurl>According to The Fly, JPMorgan acknowledged that the WSJ report is "clearly not a positive" but says the potential cuts wouldn't impact access to PrEP (pre-exposure prophylaxis). The firm noted that the CDC doesn't reimburse PrEP drugs but funds research and education.&nbsp;The research firm remains bullish on Gilead's lenacapavir — a twice-yearly injectable HIV-1 capsid inhibitor — as a key growth driver and maintains an 'Overweight' rating on the stock.Oppenheimer sees Gilead's pullback as a reaction to uncertainty but doesn't view the funding concerns as a material risk. The firm estimates PrEP revenues account for just 8% of Gilead's total sales, with Medicaid representing an even smaller fraction.&nbsp;It expects early lenacapavir adoption mostly from private insurers and reiterated an 'Outperform' rating with a $132 price target.If approved by the Food and Drug Administration, Morgan Stanley reportedly estimates that lenacapavir could generate annual sales of over $6 billion by 2030.According to Koyfin data, Gilead stock currently trades at a 13.5x forward earnings multiple, compared to Eli Lilly's 36.1x and Amgen's 15.3x.Shares of Gilead are up 16% this year, outperforming the NASDAQ Biotechnology Index's 3% gain.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gilead Sciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.

Equity

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.


HP, Inc. (<a class="mention" data-mention="$HPQ" data-symbol-id="HPQ" href="https://stocktwits.com/symbol/HPQ" target="_blank">$HPQ</a>) shares fell sharply in Wednesday’s premarket session after the Palo Alto-based company announced fiscal year 2024 fourth-quarter results roughly in line with expectations and running quarter guidance that trailed, reflecting the ongoing weakness in the global PC industry.&nbsp;The manufacturer of personal computing, printing, 3D printing, and gaming products, said its fourth-quarter non-GAAP earnings per share came in at $0.93, within the guidance range of $0.89-$0.99 and in line with the consensus.Net revenue rose a modest 1.7% year-over-year (YoY) to $14.1 billion compared to the $13.99&nbsp;billion consensus estimate. Personal systems net revenue climbed 2% to $9.6 billion,&nbsp;representing around 68% of the total, and printing net revenue was up 1%.Estimates from Gartner&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gartner.com/en/newsroom/press-releases/2024-10-09-gartner-says-worldwide-pc-shipments-declined-1-percent-in-third-quarter-of-2024">showed</a> global PC shipments falling 1.3% YoY to 62.9 million units in the third quarter, with HP’s shipments seeing a marginal YoY drop.Enrique Lores, HP President and CEO, said, "We are pleased with our Q4 performance where we saw revenue growth for the second consecutive quarter, driven by steady progress in Personal Systems and Print."HP said it returned $1.2 billion to shareholders in the form of share repurchase and dividends.&nbsp;The company announced a 5% increase to its annual dividend. The board declared a $0.2894 quarterly dividend, payable on Jan. 2, 2025, to shareholders of record as of Dec. 11, 2024.Looking ahead, HP expects non-GAAP EPS of $0.70-$0.76 for the first quarter of the fiscal year 2025 and $3.45-$3.75 for the full year. Analysts, on average, expect the metrics to come in at $0.82 and $3.60, respectively.&nbsp;CFO Karen Parkhill said, “As we look ahead, we are well positioned to deliver solid growth across revenue, non-GAAP net earnings, EPS and free cash flow in FY25.”As of 8:30 a.m. ET in premarket trading, HP shares were trading down 8.26% at $35.87. The stock, though, has gained over 33% so far this year.<figure class="image"><a href="https://stocktwits.com/symbol/HPQ"><img style="aspect-ratio:630/131;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/hp_sentiment_df3a5935b3.png" alt="hp-sentiment.png" width="630" height="131"></a><figcaption>HP sentiment and message volume November 25, 2024, premarket as of 8:30 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits platform, sentiment toward the stock flipped to ‘extremely bearish’ (5/100) from ‘extremely bullish,’&nbsp;marking a year-low. Meanwhile, message volume&nbsp;climbed further into the&nbsp;‘extremely high’&nbsp;(97/100) territory, the highest it has been this year.Rival Dell Technologies, Inc. ($DELL), despite the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dell-q3-2025-earnings-beat-estimates-revenue-trails/cJI0ul9RW3">post-earnings plunge,</a> was viewed more positively by retailers, given its exposure to artificial intelligence servers.&nbsp;For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rambus-initiated-at-outperform-at-baird/cJIWrizRgU">Rambus Stock Powers Up After Memory Chipmaker Snags A Bullish Rating: Retail Upbeat</a>

Global PC shipments fell 1.3% YoY in Q3, according to Gartner.

HP Q4 Results Deflate Retail Mood: Stock Sinks Over 8% As In-Line Quarterly Results, Sub-par Guidance Worry Traders

HP reported low single-digit revenue growth for its personal systems as well as printing segments.

ZoomInfo Technologies, Inc. ($ZI), a B2B platform that offers a commercial search-engine for companies and businesses, reported third-quarter results that exceeded expectations and issued fairly in-line guidance for the fourth quarter and the full year.Vancouver, Washington-based ZoomInfo reported third-quarter non-GAAP earnings per share of $0.28, up from $0.26 earned a year-ago. The bottom-line result exceeded the consensus estimate of $0.22.Revenue, however, fell 3% year-over-year (YoY) to $303.6 million and yet surpassed the $299.36-million consensus estimate.Henry Schuck, ZoomInfo founder and CEO, said, "We continued our move up-market, fueled by ZoomInfo Copilot and Operations growth, and we delivered strong financial results while improving the quality of new customers that we are bringing in.""The entire company is more focused than ever on delighting both our new and existing users via robust product innovation and customer obsession."The company noted that net revenue retention was stable for the third consecutive quarter, as it grew its $100,000 and million-dollar customer cohorts yet again.&nbsp;Looking ahead, the company narrowed its full-year revenue guidance from $1.19 billion-$1.205 billion to $1.201 billion-$1.204 billion. It raised its non-GAAP EPS guidance from $0.86-$0.88 to $0.92-$0.93.&nbsp;Analysts, on average, expect revenue of $1.2 billion and non-GAAP EPS of $0.90.ZoomInfo guided to fourth-quarter revenue of $296 million-$299 million and non-GAAP EPS of $0.22-$0.23. This compares to the consensus estimates of $296.91 million and $0.23, respectively.Following the results, Mizuho raised the price target for the stock from $9 to $11 while maintaining a Neutral rating, the Fly&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/news.php?symbol=ZI">reported.</a> The firm described the quarter as "healthy," and also noted that the management sees small business write-offs abating.&nbsp;The company was seeing traction with its artificial intelligence offerings and the CoPilot solution, especially with mid-market and enterprise segments, the firm added.Retailers on the Stocktwits platform were mixed about the stock. One of them said the company is struggling in one of the best macro environments in history.<stembedurl>https://stocktwits.com/ASAP17/message/592252559</stembedurl>Another termed the stock as a “catch-up play” and noted that the short interest was high.<stembedurl>https://stocktwits.com/Chickenstick1/message/592245466</stembedurl>In premarket trading as of 8:40 am ET, the stock was down a steep 12.84% to $11.40.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cava-reports-2024-q3-beat-lifts-guidance/cJ4jPR2ROH">CAVA Stock Soars As Tasty Q3 Results Earn Wall Street Cheers, But Retail Appetite Mixed</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

ZoomInfo said net revenue retention was stable for the third consecutive quarter. 

ZoomInfo Stock Plunges Despite Q3 Beat As Traders Fret Over Shrinking Revenue: Retail Remains Wary

ZoomInfo CEO Schuck said the company is focused on satisfying new and existing customers through product innovation and customer obsession.

Pacer Funds Trust - Pacer US Cash Cows 100 ETF

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

COWZ
Pacer Funds Trust - Pacer US Cash Cows 100 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest COWZ News

COWZ Pacer Funds Trust - Pacer US Cash Cows 100 ETF